ApoLife Inc.

ApoLife has developed platform expression technologies for the rapid and efficient screening and production of recombinant proteins and functional human antibodies..

ApoLife’s process requires 1/3 the time for production thus lowering the cost of capital investment and has the potential of lowering the cost of final products by up to 50%. The company employs Bakers yeast, Saccharomyces cerevisiae, which has been used in manufacturing several FDA approved therapeutic products thereby providing competitive regulatory advantages over other alternate expression systems. By applying ApoLife’s proprietary "Twin Cassette" expression system, biopharma and biotechnology companies can accelerate the process of bringing the new therapies to market and help reduce the healthcare costs.

Primary Activity